Article
House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control -- a RWE study
2023-05-08
Abstract excerpt
<h4>Background: </h4> The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval in Germany and therefore will be available after the scheduled completion of the TAO procedure in 2026. In general, data from clinical trials on the long-term effectiveness of HDM AIT a...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7a78b2a8-c0be-5117-8b7a-d966e1f09c27
- DOI
- 10.22541/au.168351492.25008933/v1
